Innvolution Healthcare secures license for cardiac cath lab production at AMTZ
Innvolution Healthcare has received a license to manufacture cardiac catheterization labs at the Andhra Pradesh MedTech Zone. This move is intended to reduce India's reliance on imported medical equipment and address the country's significant deficit in cardiovascular care infrastructure.
Why it matters
Domestic production of high-end medical technology is a key component of India's strategy to improve healthcare accessibility and reduce costs.
Innvolution Healthcare Private Limited (IHPL) has been recently granted the CDSCO manufacturing license for its Cardiac catheterisation laboratory (cath lab) facility in Andhra Pradesh MedTech Zone (AMTZ).
The facility, recently inaugurated by the Union Minister of Commerce and Industry, Piyush Goyal, represents a strategic move toward bolstering India’s domestic capacity to produce advanced cardiac imaging systems.
The development comes at a time when the nation’s cardiovascular infrastructure faces a severe deficit, while the cardiovascular diseases are claiming nearly three million lives annually and impacting nearly 80 million patients. India currently hosts only about 4,000 active cardiac catheterisation labs, a limitation that has historically restricted access to advanced cardiac care.
Experts believe that shifting from expensive imported systems to domestic manufacturing will be pivotal in enhancing hospital affordability and expanding the reach of life-saving treatments.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in